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?VITAMIN D PRESCRIBING HABITS AND CLINICAL OUTCOME IN 
PEDIATRIC PATIENTS WITH INF?AMMATORY BOWEL DISEASE 
TIMOTHY YANG 
 
ABSTRACT 
INTRODUCTION: The inflammation observed in patients with IBD can negatively 
impact the intake or absorption of vitamin D. This can increase the risk of disease 
relapse, impact patients’ quality of life, and increase the risk of IBD related surgeries. In 
addition to the traditional observation that vitamin D deficiency may be a comorbid 
manifestation of IBD, there is now growing evidence pointing to serum vitamin D levels 
as a pathogenic factor contributing to the initiation and propagation of mucosal 
inflammation in patients with IBD. It is well-established that variation in clinical practice 
leads to less optimal outcomes in any clinical setting. The relative scarcity of clinical and 
translational studies is even more pronounced in the pediatric population. 
OBJECTIVES: The primary objective of this study is to quantify the prevalence of 
clinician assessment of vitamin D levels in pediatric patients with IBD. We will also look 
at this behavior in subpopulations and compare their vitamin D status. It is secondary for 
this study to also describe variations in physician practices with respect to the testing and 
treatment of vitamin D deficiency at a single tertiary care IBD Center.  
METHODS: We conducted a retrospective cohort study on consecutive patients with UC, 
CD, and ID, that were followed in the ambulatory program in the Center for 
Inflammatory Bowel Disease at Boston Children’s Hospital from 1/1/2014 to 12/31/2014. 
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We identified 498 patients and collected their demographic information, serologic testing, 
and physician prescribing behavior.  
RESULTS: Out of the entire population, 64% of the patients were vitamin D deficient 
(vitamin D level below 32 ng/ml). 24% of the patients received vitamin D 
supplementation. Vitamin D deficiency was less prevalent in patients with UC than those 
with CD, with an OR of 0.64 (95% CI 0.43-0.94). Out of the ones receiving 
supplementation, 37% of them were deficient. In terms of physician practice trends, 62% 
of the patients were not formally prescribed supplementation. 14.5% of those who were 
prescribed supplementation were receiving 50,000 IU weekly, and the rest receiving 400 
– 2,000 IU daily. Patients with vitamin D levels below 20 ng/ml were more likely to 
receive the high dose vitamin D prescription (OR 11.5) than those with levels between 20 
and 30 ng/ml (OR 5.7).  
CONCLUSIONS: Our study suggests that despite high prevalence of vitamin D 
deficiency in pediatric patients with IBD, there is a lack of consensus with respect to the 
assessment of vitamin D levels and consistency in prescribing vitamin D 
supplementation. With the potential role that vitamin D plays in IBD pathology and 
suggestions of the therapeutic effects of vitamin D supplementation, further studies are 
needed to explore this area.  
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INTRODUCTION 
 
Vitamin D  
 Vitamin D is a family of fat-soluble steroids that can be derived from either 
dietary sources (Vitamin D2, ergosterol), or synthesized in the skin (Vitamin D3, 
cholecalciferol) from the dermal precursor 7-dehydrocholesterol under the influence of 
UV light. Since there are only a few foods like dairy and fish that are rich sources for 
plant sterol ergosterol, the precursor of vitamin D2, dermal synthesis is typically the 
primary source of vitamin D available to meet metabolic demands. Vitamin D3 and 
vitamin D2 are both biologically inactive. Hydroxylation of vitamin D2 into 25-
hydroxyvitamin D2 (25(OH)D2), or vitamin D3 into calcitriol (1,25(OH)2D3) converts 
these pro-compounds into their metabolically active derivatives, and both are able to bind 
to peripheral vitamin D receptors. Sunlight absorption during the fall and winter months 
decreases significantly in geographic regions remote from the equator, and for this 
reason, there is variation in the levels of circulating vitamin D measured in patients from 
season to season.  As such, enteric vitamin D supplementation becomes increasingly 
important during periods of little/no sun exposure. 
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Figure 1: family of vitamin D compounds (images obtained and edited from 
pubchem.ncbi.nlm.nih.gov)  
 
Vitamin D plays an essential role in human physiology. Its effects on bone health 
and mineral balance have been well-established in previous studies. It was initially 
identified as a critical regulator of calcium homeostasis and bone growth and remodeling.  
The endocrine system responds to low circulating calcium concentrations by releasing 
parathyroid hormone, and this signals the kidney to produce 1,25(OH)2D3, which in turn 
promotes increased calcium absorption from the lumen of the intestine.  Deficiencies in 
serum vitamin D levels, resulting from either poor intake or an inability to transform 
vitamin D precursors to metabolically active forms, can present clinically as rickets in 
children and osteomalacia in adults. Both of these disorders are characterized by poor 
bone mineralization, bowing of legs, muscle weakness, and musculoskeletal pain. Excess 
vitamin D resulting in vitamin D toxicity is quite rare, and typically the result of excess 
supplementation. The clinical sequelae of hypervitaminosis D include hypercalcemia, 
proteinuria, and kidney disease.  
  
3 
 More recent data has demonstrated that vitamin D also plays a critical regulatory 
role in immune cell maturation and anti-inflammatory responses (Aranow, 2011). Modlin 
et al. demonstrated that stimulation of macrophages leads to the endogenous production 
of circulating 1,25(OH)2D3 (Liu, Krutzik, & Modlin, 2007). In addition, 1,25(OH)2D3 
binding to vitamin D receptors induces the production of antimicrobial peptides. These 
findings indicate local 1,25(OH)2D3 synthesis is part of the innate immune response to 
pathogens (White, 2016). This is of particular relevance to clinicians involved in the care 
of patients with inflammatory bowel disease.  
 
Figure 2: Schematic of vitamin D receptor signaling – VDR bound to 1,25(OH)2D3 and 
its downstream antibacterial mechanisms. (White, 2016) 
 
Inflammatory Bowel Disease 
Inflammatory Bowel Disease (IBD) refers to a collection of chronic inflammatory 
disorders affecting primarily the lining of the gastrointestinal tract. The current 
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understanding of its pathogenesis suggests that the disease results from an abnormal 
response to commensal bacteria in the lumen of the intestine, likely resulting from as of 
yet undisclosed genetic factors. IBD can be characterized into two main subtypes: 
ulcerative colitis (UC) and Crohn Disease (CD), with those difficult to distinguish 
grouped as indeterminate colitis (ID).   
The inflammation observed in patients with UC is typically limited to the colon.  
It only affects the colon’s luminal surface, or the mucosa lining, and the inflammation is 
contiguous in distribution.  Inflammation extending from the rectum to the ileocecal 
valve, which is more common in children presenting with UC, is termed “pan-colitis”. 
UC is termed “left-sided”, when the inflammation occurs exclusively in the last third of 
the colon (and past the splenic flexure).  In contrast, the inflammation observed in 
patients with CD can affect any portion of the gastrointestinal tract, extending from the 
mouth to the anus. The majority of patients with CD present with disease in the terminal 
ileum, cecum, and ascending colon.  Endoscopic evaluation of patients with CD, often 
reveals inflammation in a patchy distribution with normal appearing bowel interspersed 
between inflamed regions. The inflammation in patients with CD can be penetrating and 
extend from the mucosa to include the submucosa, muscularis externa, and serosa. 
Differentiating the two types of disease is important, as different agents may be more 
effective in treating specific IBD phenotypes.  
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Figure 3: Colon gross and histological images (Geboes et al., 1999) 
 
 Despite the geographic and histologic differences evident in patients with UC and 
CD, there are many patients with family histories, clinical presentations, or 
endoscopic/radiologic findings that preclude a certain assignment of a particular 
diagnosis, and these patients are characterized as having indeteminate colitis.  While it is 
important to appropriately categorize all patients with IBD as possessing either UC or 
CD, it is important to recognize the complexity these disorders and how they present. 
This understanding is imperative when operating in either clinical or research contexts.  
 6 
 
 
 
Figure 4: Crohn’s Disease vs. Ulcerative Colitis (Singh et al., 2010) 
 
Disease Indices: PUCAI vs. PCDAI 
Disease activity in pediatric patients with UC and CD is assessed using the 
Pediatric Ulcerative Colitis Activity Index (PUCAI) and the Pediatric Crohn’s Disease 
Activity Index (PCDAI), respectively. These contain subjective, patient or parent-
reported outcome measures including abdominal pain, visualization of rectal bleeding, 
number of bowel movements over the course of the day, and a patient’s perceived level 
of activity level. The responses to these questions are then scored to derive an aggregate 
PUCAI or PCDAI score, which is then used to track changes in disease activity over 
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Figure 4: Crohn’s Disease Vs  Ulcerative Colitis (Singh et al., 2010) 
 
Disease Indices: PUCAI vs PCDAI  
Disease activity in pediatric patients with UC and CD is assessed using the 
Pediatric Ulcerative Colitis Activity Index (PUCAI) and the Pediatric Crohn’s Disease 
Activity Index (PCDAI), respectively. These contain subjective, patient or parent-
reported outcome measures including abdominal pain, visualization of rectal bleeding, 
number of bowel movements over the course of the day, and a patient’s perceived level 
of activity level. The responses to these questions are then scored to derive an aggregate 
PUCAI or PCDAI score, which is then used to track changes  in disease activity over 
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time. While these indices cover much of the symptoms characterized by these diseases 
and can be used for both clinical and research efforts, they can be noisy measurements 
and neither is comprehensive or fully reproducible. Therefore, researchers continue to 
rely on objective measures of disease activity including serum measurements of white 
count, hemoglobin, albumin, or CRP in their assessments of their patient’s disease 
activity.  
Table 1: Pediatric Ulcerative Colitis Activity Index (PUCAI) (Turner et al., 2011) 
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Table 2: Abbreviated Pediatric Crohn’s Disease Activity Index (PCDAI) 
 (Rufo & Bousvaros, 2007) 
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Role of Vitamin D in IBD  
The inflammation observed in patients with IBD can impact negatively on the 
intake or absorption of vitamin D. As such, studies have shown that anywhere from 16-
95% of patients with UC or CD suffer from vitamin D deficiency, defined as levels ≤ 20 
ng/ml (H. M. Pappa et al., 2012). In children, patients with UC tend to have lower 
vitamin D levels than those with CD (Ahlawat, Weinstein, & Pettei, 2017). Vitamin D 
deficiency can be chronic and if left untreated, and it can increase the risk of disease 
relapse, impact on a patient’s the quality of life, and increase the risk of IBD related 
surgeries (Ananthakrishnan et al., 2013). Thus, it is important to monitor IBD patients for 
low vitamin D levels and initiate supplementation regimens if clinically indicated.  
In addition to the traditional observation that vitamin D deficiency may be a 
comorbid manifestation of IBD, there is now growing evidence pointing to serum vitamin 
D levels as a pathogenic factor contributing to the initiation and propagation of mucosal 
inflammation in patients with IBD. Pappa et al. demonstrated a negative correlation 
between the clinical course of patients with IBD and their vitamin D levels (H. M. Pappa 
et al., 2012).  However, this does not establish causality, and to date there is limited 
prospective data evaluating the therapeutic efficacy of supplemental vitamin D in IBD 
patients, especially in the pediatric population.  
 
Prescription of Vitamin D for patients with IBD 
Current guidelines suggest that adult patients should have their vitamin D levels 
checked periodically and be actively supplemented to maintain their serum 25-OH 
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vitamin D levels greater than 30 ng/ml (H. M. Pappa et al., 2014).  There is currently only 
one article in the pediatric literature outlining consensus recommendations for screening 
for 25-OH vitamin D levels (Rufo & Bousvaros, 2007). Levels of at least 32 ng/mL are 
necessary to suppress PTH and increase intestinal calcium absorption (H. M. Pappa et al., 
2014). In addition to the lack of official evidence based guidelines to check vitamin D 
levels, there is also a lack of literature on the prescription and dosing of vitamin D 
supplementation for those presenting with deficiency. Physicians currently prescribe 
continuous supplements, ranging from 200-2,000 IU daily, or interval supplements of 
50,000 IU weekly. If they deem the deficiency as a minor risk, some simply suggest their 
patients to get over-the-counter vitamin D supplements. It is well-established that 
variation in clinical practice likely leads to poor outcomes in any clinical setting. The 
absence of clinical and translational studies in this area is even more pronounced in the 
pediatric population.  
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OBJECTIVES 
 
 The primary objective of this study is to examine variance in vitamin D 
surveillance and supplementation practices in a population of patients with IBD receiving 
their care in an academic tertiary care center.  We will also examine differences in 
vitamin D surveillance practices in subpopulations of pediatric patients with IBD along 
dimensions including gender, disease type, and disease location. A secondary aim of this 
study is to describe variations in physician practices with respect to the treatment of 
pediatric patients with vitamin D deficiency.  
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MATERIALS AND METHODS  
 
Study Population 
 We conducted a retrospective cohort study on consecutive patients with 
UC, CD, and ID, that were followed in the ambulatory program in the Center for 
Inflammatory Bowel Disease at Boston Children’s Hospital from 1/1/2014 and 
12/31/2014.  The inclusion criteria for this study included patients with an IBD diagnosis, 
and have at least one vitamin D level checked during their stay at the hospital. Serum 
vitamin D concentration was analyzed using 25-hydroxy chemiluminescent immunoassay 
during their clinic course as part of their care. Patients with pouchitis, inflammation of an 
artificial rectum surgically made for the management of IBD, were excluded due to its 
unique pathology.  
We identified 498 patients who met these criteria and had complete datasets 
through Childrens360, a software application that permits population based studies on 
patients admitted to Boston Children’s Hospital. Patients were also identified through the 
electronic medical record. This study was approved by the institutional review board 
(IRB) at Boston Children’s Hospital (Protocol #P00021474).  
 
 
Vitamin D Deficiency 
 Vitamin D deficiency was defined as serum vitamin D levels below 32 ng/ml in 
this study based on a number of reasons. Despite the Institute of Medicine and the 
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American Academy of Pediatrics endorsing for a serum level of greater than 20 ng/ml 
based on its association with rickets, studies in adults have shown that only with levels 
exceeding 32 ng/ml can patients have maximal suppression of parathyroid hormone 
production and optimal calcium absorption (H. M. Pappa et al., 2014). In addition, 
preexisting conditions such as cystic fibrosis, chronic kidney disease, and IBD, lead to 
higher risk of vitamin D deficiency. Guidelines from representing organizations have also 
recommended higher vitamin D levels for sufficiency status (H. M. Pappa et al., 2014). 
No studies have identified optimal vitamin D levels in pediatric patients.  
 
Study Data 
Data collected include patient demographics (MRN, date of birth, sex, BMI, 
ethnicity, race, and IBD diagnosis), serologic testing, and physician prescribing behavior. 
Laboratory data include complete blood count with differential, electrolytes, liver panel, 
and inflammatory markers. Data were collected at time of admission and at the first 
follow-up ambulatory visit. Physician practice data include frequency of vitamin D 
checks, dates of the checks, vitamin D supplementation prescription, supplementation 
dosage, and whether patients have pre-existing vitamin D supplementation. These 
parameters were also collected at both admission and follow up visit. No over-the-
counter vitamin D supplementation information was available and could not be collected, 
and compliance with prescribed medication was assumed.  
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Case Report Form 
 The case report form (CRF) was created on Research Electronic Data Capture 
(REDCap), a secure web application that is compliant with HIPAA standards, and used to 
collect data from PowerChart. It facilitated data entry and data storage on a day-to-day 
basis during the collection process. The CRF includes four sections, demographic data, 
vitamin D data, physician behavior, and outcomes. While not all of the data collected 
were used for this study, the CRF was designed to collect a comprehensive set of data to 
account for all possible confounders and to have the potential for other studies on the 
same population.  
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Figure 5: CRF demographic data and vitamin D data 
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Figure 6: CRF vitamin D data – serological 
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Figure 
7: CRF vitamin D data – follow up 
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Figure 8: CRF physician behavior data and outcomes data  
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Figure 9: CRF outcomes data  
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RESULTS 
 
Patient Characteristics 
We collected data from 498 patients for this study, with the patient characteristics 
detailed below in Table 3. The population is 58% male, with an average of 17.6 year of 
age (SD 4). 64% of the patients were diagnosed with CD, 35% with UC, and the 
remaining 1% with ID. Out of the entire population, 318 patients (64%) were vitamin D 
deficient (vitamin D level below 32 ng/ml), and 118 patients (24%) were receiving 
vitamin D supplementation. Of the vitamin D deficient patients, their average vitamin D 
level was 24 ng/ml. Of the patients receiving vitamin D supplementation, 44 (37%) were 
vitamin D deficient.  
The characteristics of the 318 (64%) of the vitamin D deficient patients at the time of 
their initial 2014 vitamin D check are displayed in Figure 11. More males than females 
were deficient with an odds ratio (OR) of 1.9 (95% CI 1.3-2.7). Vitamin D deficiency 
was less prevalent in patients with UC than those with CD, with an OR of 0.64 (95% CI 
0.43-0.94). However, the significance is less pronounced when controlling for gender, 
vitamin D supplementation, and time of year (OR 0.6, 95% CI 0.42-1.0). There is no 
significant difference between high sunlight and low sunlight groups (OR 0.76, 95% CI 
0.48-1.02).  
Of the 118 (24%) patients that received prescription vitamin D supplementation, there 
is a significant reduction of the prevalence of vitamin D deficiency. The OR of vitamin D 
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deficient patients over sufficient patients was 0.2 (95% CI 0.13-0.3). We did not assess 
the temporal aspects of vitamin D supplementation, since documentation in this area was 
roughly estimated.   
 
Table 3: patient characteristics at baseline  
PATIENT CHARACTERISTICS ALL (N = 498)  
DEMOGRAPHICS   
 AGE  17.6 ± 4 
 MALE GENDER  288 (57.8%) 
DISEASE   
 DIAGNOSIS (CD) 319 (64%)  
 DIAGNOSIS (UC) 174 (35%) 
 DIAGNOSIS (ID)  5 (1%)  
VITAMIN D STATUS   
 VITAMIN D DEFICIENT 318 (63.8%)*  
 VITAMIN D 
SUPPLEMENTATION 
118 (23.7%)** 
*Vitamin D deficient patients had an average vitamin D level of 23.8 ng/ml (SD 5.9).  
**Out of the patients who received Vitamin D supplementation, 44 (37.3%) were vitamin 
D deficient.   
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Figure 10: Deficiency and supplementation in study population. Total = 498. 
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*adjusted using regression for gender, time of year, and vitamin D supplementation  
Figure 11: vitamin D deficient patient characteristics  
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Figure 12: Percentage per month of vitamin D deficient and sufficient patients. Goal time 
frame for initial check outlined in red. 
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Physician Practice Trends 
Next we looked at physician behavior regarding vitamin D levels. Initial testing for 
vitamin D levels was most frequent during the month of January. In the vitamin D 
deficient population, 61.6% were not formally prescribed vitamin D supplementation. Of 
the ones prescribed, 14.5% received the high dose of 50,000 IU weekly for 7 weeks while 
others received the low dose of 400 – 2,000 IU daily. No vitamin D sufficient patients 
received high dose vitamin D supplementation. A total of 414 (82.7%) patients had 
follow up testing for vitamin D levels.  
Patients with vitamin D levels less than 20 ng/ml (severely deficient) were more 
likely to receive the high dose vitamin D prescription than those with vitamin D levels 
between 20 and 30 ng/ml (mildly deficient) (OR 9.7, 95% CI 4.7 – 19.8). In addition, 
when comparing to the vitamin D sufficient group, there was a greater difference between 
prescribed vitamin D supplementation for severely deficient patients and sufficient 
patients (OR 11.5, 95% CI 6.4 – 21.6). The difference was smaller in prescribing 
supplementation for mildly deficient patients and sufficient patients (OR 5.7, 95% CI 3.3 
– 9.8).  
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DISCUSSION 
 
The primary goal of this study was to quantify prevalence of vitamin D deficiency 
and assess physician-prescribing habits with respect to vitamin D surveillance and 
supplementation.  Our study population was a retrospective cohort consisting of 498 
patients receiving care in the ambulatory care center at Boston Children’s Hospital.  We 
defined vitamin D deficiency as 25-OH Vitamin D levels below 32 ng/ml. While both the 
Institute of Medicine and the American Academy of Pediatrics have endorsed a serum 
vitamin D level of 20 ng/ml as sufficient, studies in adults show that a level of at least 32 
ng/ml is necessary for optimal calcium absorption and suppression of parathyroid 
hormone (H. Pappa et al., 2011). In addition, vitamin D levels below 35 ng/ml have been 
shown to increase the risk of subsequent disease flare in patients with UC (Gubatan et al., 
2017). Vitamin D deficiency also increases the risk of IBD related surgeries 
(Ananthakrishnan et al., 2013). Using levels below 32 ng/ml as a cut-off, our data 
demonstrated that 64% of the IBD patients at Boston Children’s Hospital suffered from 
vitamin D deficiency.  
The next aim of this study was to examine data collected from subpopulations 
drawn from within our study cohort in an effort to gain better insights into the presence 
and rationale behind disparate vitamin D surveillance practices in patients with UC as 
opposed to those with CD. We found that patients with UC were 40% more likely to have 
vitamin D deficiency than those with CD (OR = 0.64, 95% CI 0.43-0.94). The 
discrepancy in vitamin D levels observed in patients with UC and CD is poorly 
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characterized in the literature, but our data agreed with those reported in recent studies. In 
addition to Pappa et al., two other groups have found that vitamin D deficiency is more 
prevalent in patients with UC than in those with CD (El-Matary, Sikora, & Spady, 2011; 
Veit, Maranda, & Nwosu, 2015). One study found that 76% of their UC patients were 
vitamin D deficient as opposed to 79% of the CD patients, but the difference was not 
statistically significant when controlling for confounding variables (Dumitrescu, Mihai, 
Dranga, & Prelipcean, 2014). While incompletely understood, data from a preponderance 
of studies suggests that there is a higher frequency of vitamin D deficiency in patients 
with UC, relative to those with CD.  
A previous study focused on physician screening practices and the initiation of 
vitamin D supplementation. Serum vitamin D checks were most frequent in the month of 
January (26%). While it is considered one of the “low sunlight months” especially in 
northeastern United States, one study has suggested that screening be done in late winter 
and early spring (H. M. Pappa et al., 2014). Within the vitamin D deficient population, 
over 60% of the patients were not formally prescribed vitamin D supplementation. Of the 
ones prescribed, about 15% received the high dose vitamin D supplementation (50,000 
IU) weekly, while others received 400-2,000 IU daily. When compared to vitamin D 
sufficient patients, there is a significant difference in prescribing behaviors suggesting a 
therapeutic effect on supplementation to correct vitamin D deficiency.  
Screening for vitamin D deficiency can be difficult, but nonetheless quite 
essential to avert the detrimental effects of chronic iron deficiency. Our study showed an 
inconsistency in vitamin D assessment in our population.  There are several potential 
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contributors to this shortfall. First, there is currently no evidence-based guidelines 
articulating specific vitamin D screening paradigms in pediatrics.  This charges 
physicians with the prerogative to use their own discretion in deciding when they should 
check vitamin D levels in their patients with IBD.  Some clinicians may choose to not 
think about vitamin D levels when treating patients with IBD, while others may think 
their patients too sick to worry about their vitamin D levels. Moreover, physicians may 
worry that an additional supplementation to the patients’ already complex treatment 
regimens could place unnecessary burdens on the patients and their family. Lastly, some 
gastroenterologists believe that vitamin D deficiency is merely a symptom of IBD, and 
once they manage the disease, vitamin D levels will fix themselves (H. M. Pappa et al., 
2014).  
However, there is strong evidence for the benefits of treating vitamin D 
deficiency in the IBD setting. Studies have shown a negative correlation between vitamin 
D status and severity of IBD (H. M. Pappa et al., 2012). In a randomized double-blind 
placebo-controlled trial, patients with CD who received vitamin D supplementation along 
with calcium daily for a year showed a lower rate of clinical relapse (Jorgensen et al., 
2010). In addition, the dosage of vitamin D supplementation plays an important role in 
the treatment of deficiency.  
Our study demonstrated that as the severity of vitamin D deficiency increased, 
prescription of the higher dosage became more prevalent. This agrees with a prospective 
study showing that the high dose 50,000 IU weekly is preferential to 2,000 IU daily (H. 
M. Pappa et al., 2012). The same study suggested that compliance may be a factor in the 
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preference of high dose interval supplementation, since patients tend to skip their 
medications while having to take pills more frequently.  
While there is inconsistency in physician practice for prescribing vitamin D 
supplementation to patients suffering from deficiency, it has been demonstrated that high 
dose oral vitamin D supplementation can increase serum vitamin D levels in a short 
amount of time when administered at high doses (H. M. Pappa et al., 2012). Along with 
the correlation between high vitamin D levels and increased rates of IBD remission, 
vitamin D supplementation is an attractive therapeutic option to treat vitamin D 
deficiency and better manage IBD in pediatric patients.  
The present study has some limitations. The retrospective design is subject to 
selection bias and information bias. In addition, it cannot control for exposure or outcome 
assessment, and is only as good as the record keeping. Specifically, there were no record 
of over-the-counter vitamin D supplementation, which could affect individuals’ vitamin 
D levels. In addition, we had to assume compliance with their prescribed 
supplementation, but in reality there is typically a component of inherent noncompliance 
with prescribed medication. Secondly, we had no information and could not quantify 
patients’ dietary intake of vitamin D, as well as sunlight exposure, both of which would 
vary greatly from patient to patient. Lastly, the study was limited to looking at physician 
practice behavior at a single center, and would not be representative of other IBD centers 
regarding the monitor and management of vitamin D deficiency. A future prospective 
study with multiple centers that allows for the collection of all relevant data will address 
each of the limitations presented in this study. Despite being limited, our study had a 
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robust population size and rigorous longitudinal data collection. In addition, being a 
single-center-study minimized variations in testing protocol and laboratory samples. It 
also allowed a more focused understanding and assessment of physician practices at one 
specific center, and could lead to immediate improvement in managing and treating 
vitamin D deficiency.  
 In summary, vitamin D deficiency is an important comorbidity in patients with 
IBD due to its prevalence and health consequences if left unaddressed. Our study 
demonstrated that there is a lack of consistency with respect to both screening for vitamin 
D deficiency as well as prescribing practices.  While our understanding of the importance 
of vitamin D with respect to bone and immune health remains incomplete, the technology 
available to surveille and treat this condition are relatively cheap and readily available to 
both primary care and GI providers.  The benefits of vitamin D sufficiency are myriad.  
As such it is imperative that we further our awareness of the prevalence and consequence 
of vitamin D deficiency and conduct additional studies to gain a better understanding of 
optimal treatment strategies.  
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CONCLUSION 
 
The objective of the study was to quantify the prevalence of vitamin D deficiency 
in pediatric patients with IBD, as well as to assess physician practice in monitoring and 
treating vitamin D deficiency. Our study suggests that despite high prevalence of vitamin 
D deficiency in pediatric patients with IBD, there is a lack of guidelines for assessment of 
vitamin D levels and consistency in prescribing vitamin D supplementation. With the 
potential role that vitamin D plays in IBD pathology and suggestions of the therapeutic 
effects of vitamin D supplementation, further studies are needed to explore this area.  
One immediate study is to investigate the outcomes of vitamin D deficiency, in 
terms of bone health and disease course. This is currently being done by Dr. Paul Rufo’s 
group at Boston Children’s Hospital as a follow up to the study presented here. This 
study will include the assessment of the actual impact of vitamin D levels on disease 
activity and provide a paradigm to treat patients found to be vitamin D deficient. The next 
step would be to design a study to give patients doses of vitamin D to directly address 
their deficiency.  
Vitamin D deficiency remains prevalent in pediatric patients with IBD. Our study 
on screening and treatment practices suggests a need for further efforts to identify and 
treat vitamin D deficiency in this developmentally and immunologically vulnerable 
population.
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